Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

$24.99

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Abbott Laboratories, common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Short-term borrowings
Trade accounts payable
Salaries, wages and commissions
Other accrued liabilities
Dividends payable
Income taxes payable
Current portion of long-term debt
Current liabilities
Long-term debt, excluding current portion
Post-employment obligations, deferred income taxes and other long-term liabilities
Long-term liabilities
Total liabilities
Preferred shares, one dollar par value, none issued
Common shares, without par value, issued at stated capital amount
Common shares held in treasury, at cost
Earnings employed in the business
Accumulated other comprehensive loss
Total Abbott shareholders’ investment
Noncontrolling interests
Total shareholders’ investment
Total liabilities and shareholders’ investment

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).


Short-term borrowings
Remained relatively stable between 0.27% and 0.31% of total liabilities and shareholders' investment during the initial periods but data is missing from March 31, 2021 onward.
Trade accounts payable
This item showed an overall increasing trend from 4.76% at the start to a peak around 6.43% by March 31, 2022, followed by a gradual decline to 4.9% by September 30, 2025, indicating fluctuating but generally rising payables in early periods with some reduction toward the later periods.
Salaries, wages and commissions
Displayed cyclical fluctuations over time, generally oscillating between around 1.4% and 2.2%, with a slight upward movement in some of the quarters in 2021 and 2023, suggesting variability in labor-related expenses relative to liabilities and equity.
Other accrued liabilities
This category generally increased from 6.6% to around 7.85% in late 2020, stabilized around 7.3% to 7.8% in early 2022, then declined gradually to about 6.98% by September 2025, reflecting changes in accrued obligations with some volatility but a mild downward trend in the long term.
Dividends payable
Exhibited a slow but steady increase from 0.95% to a peak of around 1.32% between 2020 and mid-2024, followed by a minor decline, signifying a gradual rise in dividend obligations as a proportion of total liabilities and equity.
Income taxes payable
Displayed considerable variability, initially remaining below 0.5%, then increasing after 2022 to reach about 0.96% at September 2024 before moderately declining, indicating fluctuations in tax obligations relative to total financing sources.
Current portion of long-term debt
Varied notably with dips to near zero at some quarters but also increased at times to over 3%, especially in late 2022 and 2023, suggesting refinancing or restructuring of debt schedules affecting short-term debt components.
Current liabilities
Generally trended upwards from 16.19% to a peak over 20% around late 2022 and 2024, before slightly decreasing to around 17.32%, showing an increasing share of short-term obligations over total liabilities and equity with intermittent moderation.
Long-term debt, excluding current portion
Demonstrated a consistent declining pattern from over 26% in early 2020 to about 13.78% by the end of 2025, indicating a gradual reduction in the long-term debt burden relative to total liabilities and shareholders’ investment.
Post-employment obligations, deferred income taxes and other long-term liabilities
Exhibited a steady decline from around 13% to just over 8% from 2020 through 2025, implying a decrease in long-term non-debt liabilities over the period.
Long-term liabilities
Followed a declining trend from approximately 39% to below 22%, driven mainly by reductions in long-term debt and other long-term liabilities, reflecting a lower proportion of long-term obligations in the company's capital structure over time.
Total liabilities
Declined steadily from about 54.4% in early 2020 to around 39.1% by late 2025, indicating a decreasing overall reliance on liabilities relative to shareholders’ investment in the capital structure.
Common shares, without par value, issued at stated capital amount
Remained fairly stable, fluctuating around 30% to 35%, without any pronounced long-term increase or decrease, suggesting consistent equity capital funding through issued shares.
Common shares held in treasury, at cost
Displayed a widening negative value from approximately -14.8% to nearly -22% by late 2024, then partially reversing to around -20% by 2025, indicating growing treasury stock holdings which reduce the total shareholders' equity.
Earnings employed in the business
Showed a sustained upward trend from about 38.6% to over 58% by early 2025, signifying significant growth in retained earnings or internal capital accumulation over the period.
Accumulated other comprehensive loss
Demonstrated a generally improving trend with losses shrinking from around -14% to approximately -7.9%, indicating a reduction in accumulated losses recognized in other comprehensive income.
Total Abbott shareholders’ investment
Increased steadily from roughly 45.3% to above 60%, reflecting growth in the equity portion of the capital structure, driven primarily by increases in retained earnings and relatively stable share capital.
Noncontrolling interests
Remained stable at about 0.3% throughout the periods, with minor fluctuations, showing negligible impact on overall shareholders’ equity composition.
Total shareholders’ investment
Experienced a consistent rise from approximately 45.6% to over 60%, underscoring a strengthening equity base relative to total financing and a declining reliance on liabilities.
Overall capital structure
The combined data reveals a clear shift over the years toward greater equity financing, driven by accumulation of earnings and steady share capital, while total liabilities, especially long-term debt, show a marked decline. This suggests a strategic focus on deleveraging and enhancing shareholders’ equity proportions within the total capital employed.